Altimmune Stock Price, News & Analysis

Altimmune (ALT) has secured a credit facility of up to $100 million from Hercules Capital (HTGC), with an initial $15 million tranche funded at closing. The company, which had $150 million in cash as of March 31, 2025, will use the funds to support the development of pemvidutide, its GLP-1/glucagon dual receptor agonist. The remaining tranches include $25 million available in 2025 and $60 million in 2026, subject to clinical and financial milestones.

Pemvidutide is currently in a Phase 2b IMPACT trial for MASH with top-line data expected in Q2 2025. The company also plans to initiate Phase 2 trials for Alcohol Use Disorder and Alcohol Liver Disease in Q2 and Q3 2025. The loan features interest-only payments for 24 months (extendable to 42 months) and matures in 48 months.

Altimmune (NASDAQ: ALT) reported Q1 2025 financial results and provided key business updates. The company is approaching top-line data from its IMPACT Phase 2b trial of pemvidutide in MASH expected in Q2 2025, with 212 participants enrolled. Altimmune secured a $100 million credit facility with Hercules Capital, with $15 million funded initially. The company reported cash and equivalents of $150 million as of March 31, 2025. Q1 financial results showed R&D expenses of $15.8 million (down from $21.5 million in Q1 2024) and a net loss of $19.6 million ($0.26 per share). The company also announced plans to initiate Phase 2 trials for pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) in Q2 and Q3 2025, respectively, expanding their therapeutic pipeline.

Altimmune (Nasdaq: ALT) presented new analyses at the EASL International Liver Congress™ demonstrating the effectiveness of the MASH Resolution Index (MASHResInd) in predicting MASH resolution for patients treated with pemvidutide. The analysis showed impressive response rates, with 69.2%, 92.3%, and 90.9% of subjects receiving 1.2mg, 1.8mg, and 2.4mg of pemvidutide respectively achieving MASHResInd responses, compared to just 22.2% in the placebo group. The MASHResInd algorithm, developed by Dr. Rohit Loomba, combines multiple non-invasive tests to predict MASH resolution on biopsy. These results suggest a high probability of achieving MASH resolution in Altimmune's ongoing IMPACT Phase 2b Trial, with the company expecting to report results this quarter.

Altimmune (NASDAQ: ALT), a late clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and webcast at 8:30 am E.T. on the same day, during which management will discuss the financial performance and provide a business update.

Investors can access the webcast through Altimmune's Investor Relations website, and participants wishing to join the call can register to receive dial-in information. A replay of the call will be available on the company's website for up to three months following the event.

Altimmune (Nasdaq: ALT) announced its upcoming presentation at the EASL International Liver Congress™ 2025 in Amsterdam. The company will present analyses of pemvidutide-treated subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) using the MASH Resolution Index (MASHResInd), a new non-invasive measure of MASH histologic response. Dr. Shaheen Tomah, Director of Clinical Development at Altimmune, will present findings on MASH resolution rates with pemvidutide treatment. The presentation includes a poster tour on May 8, 2025, at 9:45 am CET and a general poster session on May 10, 2025, from 12:00 PM to 1:00 PM CET.

Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Citizens Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 9:30 a.m. EDT.

Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation demonstrates the company's continued engagement with the investment community and commitment to transparency in communications.

Altimmune (Nasdaq: ALT) has announced a virtual R&D Day scheduled for March 13, 2025 at 12:00 pm Eastern Time. The event will showcase presentations from Key Opinion Leaders (KOLs) focusing on multiple therapeutic areas for pemvidutide:

• Obesity treatment applications
• MASH (Metabolic Dysfunction-Associated Steatohepatitis)
• Two additional newly FDA-cleared indications

The R&D Day will cover the scientific basis for pemvidutide across these indications, review existing clinical data, and outline development strategies. A significant highlight will be discussing the upcoming topline data from the IMPACT Phase 2b trial in MASH, expected in Q2 2025. The event will be accessible through https://investorday.altimmune.com and the company's website Events section.

Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Leerink Global Healthcare Conference in March 2025. The company's management team will engage in a fireside chat session during the conference.

The event will be accessible via webcast through the Events section of the Altimmune website, providing investors and interested parties an opportunity to follow the discussion remotely.

Altimmune (NASDAQ: ALT) has announced its Q4 and full year 2024 financial results, highlighting significant progress in its pemvidutide development program. The company reports cash reserves of $131.9 million as of December 31, 2024.

Key developments include:

• Top-line data from Phase 2b IMPACT trial in MASH expected in Q2 2025
• FDA clearance received for two additional pemvidutide indications
• Phase 2 trials for new indications to commence mid-2025

Financial highlights for Q4 2024:

• R&D expenses: $19.8 million
• G&A expenses: $5.1 million
• Net loss: $23.2 million ($0.33 per share)

The company strengthened its Board with two pharmaceutical industry veterans and plans to hold a virtual R&D Day on March 13, 2025.